{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-040396","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.694349+00:00","generated_at":"2026-06-22T03:56:30.990687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AVROBIO Q3 net loss narrows to $23M; cash runway into Q1 2024; Gaucher update Dec. 7","bullets":["Net loss of $23.0M vs $32.6M in Q3 2021; R&D expenses fell to $15.9M from $23.0M.","Cash and equivalents $116.0M as of Sept. 30, 2022, expected to fund operations into Q1 2024.","Received rare pediatric disease designation for AVR-RD-02 (Gaucher) and AVR-RD-04 (cystinosis) from FDA.","Patient dosing completed in collaborator-sponsored Phase 1/2 cystinosis trial; interim data show systemic effect.","Investor update on Gaucher disease program scheduled for Dec. 7, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-040396","json":"https://secwatch.observer/filing/0001140361-22-040396.json","markdown":"https://secwatch.observer/filing/0001140361-22-040396.md","text":"https://secwatch.observer/filing/0001140361-22-040396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/0001140361-22-040396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/ny20005640x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:56:30.990687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a57b6d4609ff4a257ee6aadbe04fcbbfadb10c3d","claim":"Tectonic Therapeutic, Inc. reported three and nine months ended September 30, 2022 results: net income $23.0 million.","evidence_excerpt":"On November 8, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/0001140361-22-040396-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Net income","value":"$23.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}